Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine(Brigham and Women's Hospital), Terje R. Pedersen(University of Oslo), Narimon Honarpour(Center for Global Development), Huei Wang(National Taiwan University), Robert P. Giugliano(Thrombolysis in Myocardial Infarction Study Group), Sabina A. Murphy(Brigham and Women's Hospital), Scott M. Wasserman(Amgen (United States)), Stephen D. Wiviott(Thrombolysis in Myocardial Infarction Study Group), Thomas Liu(Amgen (United States)), Julia Kuder(Brigham and Women's Hospital), Peter Sever(Imperial College London), Anthony Keech(Heidelberg University)
Cited by 5,966
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.1k